Top

Published in:

01-01-2021 | Breast Cancer | Original Article

Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model

Authors: Melisa B. Nicoud, Mónica A. Táquez Delgado, María de la Paz Sarasola, Agustina Vidal, Daniela Speisky, Graciela A. Cremaschi, Helena A. Sterle, Vanina A. Medina

Published in: Cancer Immunology, Immunotherapy | Issue 1/2021

Abstract

Background

The histamine H4 receptor (H4R) is preferentially expressed in immune cells and is a potential therapeutic target for inflammatory and autoimmune diseases. This study aimed at further exploring the role of H4R in the immunobiology of breast cancer.

Methods

We used wild type (WT) and H4R deficient mice (KO) to evaluate whether H4R genotypes show a different distribution of T cell subsets in spleens, tumours and tumour draining lymph nodes (TDLN) in a syngeneic ErbB2-positive breast cancer model developed orthotopically with LM3 cells and its impact on tumour growth.

Results

The presence of tumours had a differential impact on the distribution of T cells in TDLN from KO mice compared to WT ones. At day 21 post-inoculation (p.i.) of cells, despite no significant changes in the tumour weight, TDLN from KO mice showed a significantly increased proportion of CD8⁺ T cells compared to WT mice. At day 38 p.i. of cells a reduced tumour weight was evident in KO mice. This was accompanied by a decreased proportion of CD4⁺CD25⁺FoxP3⁺ regulatory T cells in TDLN of KO compared to WT mice. Tumour-bearing KO mice showed a better survival compared to WT mice.

Conclusions

H4R-mediated mechanisms may modulate the immune tumour microenvironment, promoting an immunosuppressive milieu. Results suggest that H4R could be explored as an immunotherapeutic target with potential benefit in combination with immunotherapy. Further preclinical and clinical studies are necessary to confirm this hypothesis.

Available only for authorised users

Tiligada E, Ennis M (2020) Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol 177:469–489. https://doi.org/10.1111/bph.14524CrossRefPubMed

Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WLS et al (2015) International union of basic and clinical pharmacology. XCVIII Hist Recep Pharmacol Rev 67:601–655. https://doi.org/10.1124/pr.114.010249CrossRef

O’Mahony L, Akdis M, Akdis CA (2011) Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol 128:1153–1162. https://doi.org/10.1016/j.jaci.2011.06.051CrossRefPubMed

Bäumer W, Roßbach K (2010) Histamine as an immunmodulator. J Dtsch Dermatol Ges 8:495–504. https://doi.org/10.1111/j.1610-0387.2010.07346.xCrossRefPubMed

Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K (2000) Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 279:615–620. https://doi.org/10.1006/bbrc.2000.4008CrossRefPubMed

Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R et al (2001) Discovery of a novel member of the histamine receptor family. Mol Pharmacol 59:427–433. https://doi.org/10.1124/mol.59.3.427CrossRefPubMed

Schirmer B, Rother T, Bruesch I, Bleich A, Werlein C, Jonigk D et al (2020) Genetic deficiency of the histamine H4-receptor reduces experimental colorectal carcinogenesis in mice. Cancers (Basel) 12(4):912. https://doi.org/10.3390/cancers12040912

Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ et al (2017) Clinical development of histamine H4 receptor antagonists. Handb Exp Pharmacol 241:301–320. https://doi.org/10.1007/164_2016_130CrossRefPubMed

Rossbach K, Schaper K, Kloth C, Gutzmer R, Werfel T, Kietzmann M et al (2016) Histamine H4 receptor knockout mice display reduced inflammation in a chronic model of atopic dermatitis. Allergy Eur J Allergy Clin Immunol 71(2):189–197. https://doi.org/10.1111/all.12779CrossRef

10.

Nicoud MB, Formoso K, Medina VA (2019) Pathophysiological role of histamine H4 receptor in cancer: therapeutic implications. Front Pharmacol 5(10):556. https://doi.org/10.3389/fphar.2019.00556CrossRef

11.

Kollmeier AP, Barnathan ES, O’Brien C, Chen B, Xia (Karen) Y, Zhou B et al (2018) A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma. Ann Allergy Asthma Immunol 121(5):568–574. https://doi.org/10.1016/j.anai.2018.08.001CrossRefPubMed

12.

Mehta P, Miszta P, Rzodkiewicz P, Michalak O, Krzeczyński P, Filipek S (2020) Enigmatic histamine receptor H4 for potential treatment of multiple inflammatory, autoimmune, and related diseases. Life (Basel) 10(4):50. https://doi.org/10.3390/life10040050CrossRef

13.

Hartwig C, Munder A, Glage S, Wedekind D, Schenk H, Seifert R et al (2015) The histamine H4-receptor (H4R) regulates eosinophilic inflammation in ovalbumin-induced experimental allergic asthma in mice. Eur J Immunol 45(4):1129–1140. https://doi.org/10.1002/eji.201445179CrossRefPubMed

14.

Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, Stark H, Werfel T (2009) The histamine H4 receptor is functionally expressed on TH2 cells. J Allergy Clin Immunol 123(3):619–625. https://doi.org/10.1016/j.jaci.2008.12.1110CrossRefPubMed

15.

Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC). Toxicity management working group. J immunother Cancer 5(1):95. https://doi.org/10.1186/s40425-017-0300-zCrossRefPubMedPubMedCentral

16.

O’Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16(3):151–167. https://doi.org/10.1038/s41571-018-0142-8CrossRefPubMed

17.

Palleschi M, Maltoni R, Sarti S, Melegari E, Bravaccini S, Rocca A (2020) Immunotherapy: the end of the “dark age” for metastatic triple-negative breast cancer? Breast J 26(4):739–742. https://doi.org/10.1111/tbj.13662CrossRefPubMed

18.

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1):44–59. https://doi.org/10.1016/S1470-2045(19)30689-8CrossRefPubMed

19.

Sterle HA, Nicoud MB, Massari NA, Táquez Delgado MA, Herrero Ducloux MV, Cremaschi GA et al (2019) Immunomodulatory role of histamine H4 receptor in breast cancer. Br J Cancer 120(1):128–138. https://doi.org/10.1038/s41416-018-0173-zCrossRefPubMed

20.

Nicoud MB, Sterle HA, Massari NA, Táquez Delgado MA, Formoso K, Herrero Ducloux MV et al (2020) Study of the antitumour effects and the modulation of immune response by histamine in breast cancer. Br J Cancer 122(3):348–360. https://doi.org/10.1038/s41416-019-0636-xCrossRefPubMed

21.

Urtreger AJ, Ladeda VE, Puricelli LI, Rivelli A, Del Carmen VM, De Lustig ES et al (1997) Modulation of fibronectin expression and proteolytic activity associated with the invasive and metastatic phenotype in two new murine mammary tumor cell lines. Int J Oncol 11(3):489–496. https://doi.org/10.3892/ijo.11.3.489CrossRefPubMed

22.

Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP (2003) Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305(3):1212–1221. https://doi.org/10.1124/jpet.102.046581CrossRefPubMed

23.

Lamas DJM, Nicoud MB, Sterle H, Cricco GP, Martin GA, Cremaschi GA, et al. (2017). Methodological Approaches to Investigate the Effects of Histamine Receptor Targeting Compounds in Preclinical Models of Breast Cancer. In: Tiligada E., Ennis M. (eds) Histamine Receptors as Drug Targets. Methods in Pharmacology and Toxicology. Humana Press, New York, NY pp. 353–87. 10.1007/978-1-4939-6843-5_12

24.

Su S, Liao J, Liu J, Huang D, He C, Chen F et al (2017) Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res 27(4):461–482. https://doi.org/10.1038/cr.2017.34CrossRefPubMedPubMedCentral

25.

Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS (2019) T regulatory cells and priming the suppressive tumor microenvironment. Front Immunol 10:2453. https://doi.org/10.3389/fimmu.2019.02453CrossRefPubMedPubMedCentral

26.

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 331(6024):1565–1570. https://doi.org/10.1126/science.1203486CrossRefPubMed

27.

Liu M, Guo F (2018) Recent updates on cancer immunotherapy. Precis Clin Med 1(2):65–74. https://doi.org/10.1093/pcmedi/pby011CrossRefPubMedPubMedCentral

28.

Deiteren A, De Man JG, Pelckmans PA, De Winter BY (2015) Histamine H4 receptors in the gastrointestinal tract. Br J Pharmacol 172(5):1165–1178. https://doi.org/10.1111/bph.12989CrossRefPubMedPubMedCentral

29.

Thurmond RL (2015) The histamine H4 receptor: from orphan to the clinic. Front Pharmacol 6:65. https://doi.org/10.3389/fphar.2015.00065CrossRefPubMedPubMedCentral

30.

Dunford PJ, O’Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL (2006) The Histamine H 4 Receptor Mediates Allergic Airway Inflammation by Regulating the Activation of CD4 + T Cells. J Immunol 176(11):7062–7070. https://doi.org/10.4049/jimmunol.176.11.7062CrossRefPubMed

31.

Rio R, Noubade R, Saligrama N, Wall EH, Dimitry N, Poynter ME et al (2012) Histamine H4 receptor optimizes TR cell frequency and facilitates anti-inflammatory responses within the CNS. J Immunol 188(2):541–547. https://doi.org/10.4049/jimmunol.1101498CrossRefPubMed

32.

Fransen MF, Arens R, Melief CJM (2013) Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment. Int J Cancer 132(9):1971–1976. https://doi.org/10.1002/ijc.27755CrossRefPubMed

33.

Mehdipour F, Razmkhah M, Faghih Z, Bagheri M, Talei AR, Ghaderi A (2019) The significance of cytokine-producing B cells in breast tumor-draining lymph nodes. Cell Oncol 42(3):381–395. https://doi.org/10.1007/s13402-019-00433-3CrossRef

34.

Kim CH, Lee JM, Yoo JK, Kim JS, Kim SU, Chang KT et al (2016) Inhibitory effect of imiquimod-induced psoriasis-like skin inflammation in mice by histamine H4 receptor agonist 4-methylhistamine. Scand J Immunol 83(6):409–417. https://doi.org/10.1111/sji.12420CrossRefPubMed

35.

Morgan RK, McAllister B, Cross L, Green DS, Kornfeld H, Center DM et al (2007) Histamine 4 receptor activation induces recruitment of FoxP3 + T cells and inhibits allergic asthma in a murine model. J Immunol 178(12):8081–8089. https://doi.org/10.4049/jimmunol.178.12.8081CrossRefPubMed

36.

Cowden JM, Riley JP, Ma JY, Thurmond RL, Dunford PJ (2010) Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines. Respir Res 11(1):86. https://doi.org/10.1186/1465-9921-11-86CrossRefPubMedPubMedCentral

37.

Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S et al (2010) Accumulation of Foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res 16(16):4105–4112. https://doi.org/10.1158/1078-0432.CCR-10-1073CrossRefPubMed

38.

Kay LJ, Suvarna SK, Peachell PT (2018) Histamine H4 receptor mediates chemotaxis of human lung mast cells. Eur J Pharmacol 837:38–44. https://doi.org/10.1016/j.ejphar.2018.08.028CrossRefPubMed

39.

Ehling S, Roßbach K, Dunston SM, Stark H, Bäumer W (2016) Allergic inflammation is augmented via histamine H4 receptor activation: the role of natural killer cells in vitro and in vivo. J Dermatol Sci Jap Soc Invest Dermatol 83(2):106–115. https://doi.org/10.1016/j.jdermsci.2016.04.011CrossRef

40.

Locati M, Otero K, Schioppa T, Signorelli P, Perrier P, Baviera S et al (2002) The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy 57(11):972–982. https://doi.org/10.1034/j.1398-9995.2002.02166.xCrossRefPubMed

41.

Palacios-Arreola MI, Nava-Castro KE, Castro JI, García-Zepeda E, Carrero JC, Morales-Montor J (2014) The role of chemokines in breast cancer pathology and its possible use as therapeutic targets. J Immunol Res 2014:849720. https://doi.org/10.1155/2014/849720CrossRefPubMedPubMedCentral

42.

Gao D, Rahbar R, Fish EN (2016) CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open Biol 6(6):160122. https://doi.org/10.1098/rsob.160122CrossRefPubMedPubMedCentral

43.

Bin FW, Yao M, Jokar I, Alhakamy N, Berkland C, Chen J et al (2015) The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. Breast Cancer Res Treat 150(2):309–320. https://doi.org/10.1007/s10549-015-3324-4CrossRef

Title: Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model
Authors: Melisa B. Nicoud
Mónica A. Táquez Delgado
María de la Paz Sarasola
Agustina Vidal
Daniela Speisky
Graciela A. Cremaschi
Helena A. Sterle
Vanina A. Medina
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Published in: Cancer Immunology, Immunotherapy / Issue 1/2021
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02672-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer

Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation

CD66b+ monocytes represent a proinflammatory myeloid subpopulation in cancer

Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis

Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer